Advertisement

Topics

Latest "Seattle Genetics Inc." News Stories

09:26 EST 20th February 2019 | BioPortfolio

Here are the most relevant search results for "Seattle Genetics Inc." found in our extensive news archives from over 250 global news sources.

More Information about Seattle Genetics Inc. on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Seattle Genetics Inc. for you to read. Along with our medical data and news we also list Seattle Genetics Inc. Clinical Trials, which are updated daily. BioPortfolio also has a large database of Seattle Genetics Inc. Companies for you to search.

Showing "Seattle Genetics" News Articles 1–25 of 2,100+

Wednesday 20th February 2019

Journal of Oncology Practice Publishes Study Demonstrating $3.85 Million in Reduced ED Visits for Cancer Care Providers Using Navigating Cancer Digital Platform

Analysis at two oncology practices concluded that telephone triage using symptom management pathways resulted in a significant reduction in ER events SEATTLE (PRWEB) February 20, 2019 Navigating Cancer announced today the findings of a study published in the Journal of Oncology Practice. The study quantified the savings of two mid-sized community cancer providers that utilize Navigating Cancer’...


Former Nestlé Innovation Head Valerio Nannini Joins Digital Health Company Savor Health

Savor Health is pleased to announce the addition of Valerio Nannini, former SVP, Head of Strategies and Performance at Nestle Global HQ NEW YORK (PRWEB) February 20, 2019 Savor Health is pleased to announce the addition of Valerio Nannini, former Senior Vice-President, head of Strategies and Performance at Nestlé global HQ, as a senior strategic advisor to the company. Nannini, who led Nestl...

Patients must take personal responsibility for being overweight

I’m disappointed by the simplistic arguments about whether obesity is a consequence of greed and lifestyle choices or the inevitable outcome of genetics and social inequality.1 This black and white...


Rocket Pharmaceuticals Announces Participation in Fireside Chat at the 8th Annual SVB Leerink Global Healthcare Conference

Rocket Pharmaceuticals, Inc. (Nasdaq: RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, today announces that Gaurav Shah, M.D., Chief Executive Officer and President of Rocket, will participate in a fireside chat at the 8th Annual SVB Leerink Global Healthcare Conference in New York City. The fireside chat will take pla...

Mogrify (Cell Mogrify Ltd) raises $3.7 million USD seed funding to accelerate its mission to transform cell therapy via direct cellular conversion

  Darrin M Disley, PhD, DSc, OBE, appointed as CEO New investment from Ahren Innovation Capital, 24Haymarket and Dr Disley Mogrify’s technology enables the conversion of any mature cell type into any other mature cell type without going through a pluripotent stem cell- or progenitor cell-state Promises to address the unmet market need for cell types that exhibit sa...

Recursion Named to Fast Company’s Annual List of the World’s Most Innovative Companies

Recursion, a clinical-stage biotechnology company that combines artificial intelligence (AI), experimental biology, and automation to discover and develop drugs at scale, has been named to Fast Company’s annual list of the World’s Most Innovative Companies for 2019. The list honors the businesses making the most profound impact on both industry ...

Mogrify Raises $3.7 Million USD Seed Funding to Accelerate Its Mission to Transform Cell Therapy via Direct Cellular Conversion

Darrin M Disley, PhD, DSc, OBE, appointed as CEO New investment from Ahren Innovation Capital, 24Haymarket and Dr Disley Mogrify’s technology enables the conversion of any mature cell type into any other mature cell type without going through a pluripotent stem cell- or progenitor cell-state ...

Tuesday 19th February 2019

Fulgent Genetics to Announce Fourth Quarter and Full Year 2018 Financial Results on Thursday February 28, 2019

TEMPLE CITY, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”) today announced that it will release its fourth quarter and full year 2018 financial results after the market closes on Thursday February 28, 2019. The company’s Chairman and Chief Executive Officer Ming Hsieh and its Chief Financial Officer Paul Kim will ...

Genetics Home Reference: Xia-Gibbs syndrome

Source: National Library of Medicine - Related MedlinePlus Pages: Developmental Disabilities

Westleaf: A Truly Vertically-Integrated Cannabis Play — CFN Media

SEATTLE, Feb. 19, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article covering Westleaf Inc. and their place in the … Continue reading →

CIRCULOGENE Names Anthony L. Schmidt, M.D., as Medical Director

CIRCULOGENE, advancing precision medicine through molecular genetics testing, has named Anthony L. Schmidt, M.D., F.A.C.P., as Medical Director. Dr. Schmidt will lead the laboratory’s precision medicine initiatives and work to educate the medical community about CIRCULOGENE’s molecular diagnostics capabilities and next-generation sequencing (N...

Fat Distribution Genetics Advanced through Targeting of Waist-to-Hip Ratio Genes: http://ow.ly/szcK30nKUAl pic.twitter.com/J6dYFZrR9I

Fat Distribution Genetics Advanced through Targeting of Waist-to-Hip Ratio Genes: http://ow.ly/szcK30nKUAl  pic.twitter.com/J6dYFZrR9I

Fat Distribution Genetics Advanced through Targeting of Waist-to-Hip Ratio Genes

The identification of obesity-associated genes has been a growing area of research over the last two decades, altering our understanding of obesity. A new study broadens our understanding of genes’ role in obesity by targeting body-fat distribution. Specifically, the researchers present the first association of body-fat distribution, assessed by waist-to-hip ratio (WHR) adjusted for body ...

Qiagen, Ares Genetics partner on Sample to Insight solutions for antibiotic-resistant pathogens

The agreement gives Qiagen exclusive licence to use Ares Genetics’ artificial intelligence (AI) based antimicrobial resistance database, called ARESdb. Qiagen also acquired the licence for leveraging AREStools bioinformatics The post Qiagen, Ares Genetics partner on Sample to Insight solutions for antibiotic-resistant pathogens appeared first on Compelo Medical Devices.

Donald Paul Lombardi, M.D. Joins The Oncology Institute of Hope and Innovation

The Oncology Institute of Hope and Innovation welcomes Donald Paul Lombardi, M.D., to their team of specialists. CERRITOS, Calif. (PRWEB) February 19, 2019 Dr. Lombardi is a board-certified oncologist that brings over 30 years of medical experience to The Oncology Institute of Hope and Innovation. Dr. Lombardi completed his undergraduate in Biochemistry at Bowdoin College, Brunswick, Maine, where...

Gamida Cell Announces Agreement with Editas Medicine to Evaluate Use of CRISPR Genome Editing Technology in NAM-NK Cells

Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, today announced an agreement with Editas Medicine, Inc., a leading genome editing company, to evaluate the potential use of Editas Medicine’s CRISPR technology to edit NAM-NK cells, which are natural killer cells that have been expanded using Gamida Cell’s proprietary ...

4D Molecular Therapeutics Expands Leadership Team with Appointments and Promotions of Key Executives

Company adds manufacturing and quality expertise and broad financial, operational and legal experience with the appointments of Fred Kamal, PhD as chief technical officer and head of regulatory and quality and of August Moretti as chief financial officer Company announces promotions of Peter Francis, MD, PhD to chief medical...

Nativis Announces Additional Publication of Further Study in Patients with Recurrent Glioblastoma (rGBM)

Second Study Yields Additional Data Suggesting the Nativis Voyager® is Safe for Treatment of rGBM and the Potential Breadth of Technology Platform SEATTLE (PRWEB) February 19, 2019 Nativis, Inc., (http://nativis.com) a clinical stage therapeutic device company developing non-invasive treatments for cancers and other serious diseases, today announced the publication of a second study (NAT-105...

New App, Parqueo, Launches in Seattle to Solve City’s Parking Problem

An innovative new app for parking spot owners to rent out their privately-owned parking spots in Seattle launches in the iTunes and Google Play stores. SEATTLE (PRWEB) February 19, 2019 Parqueo, a mobile app that lets Seattle locals rent out their privately-owned parking spaces launches on the iTunes and Google Play. The app serves as a platform for parking space owners to market their unused spa...

Automated microfluidics for gene editing is in the works

Oxford Genetics has announced a partnership to optimise the way laboratories deliver gene editing to cells and interrogate the resultant products

New Clinical Study Further Validates Use of ReceptivaDx™ (BCL6) Testing for Women with Unexplained Infertility by Demonstrating Successful Treatment Outcomes, Improved Live Birth Rates and Reduced Miscarriage Rates

CiceroDx, Inc., a women’s healthcare diagnostic company, is pleased to announce the publication of a pivotal study demonstrating the effectiveness of both medical or surgical treatment in unexplained infertility patients with abnormal endometrial BCL6 expression. The paper, Medical or surgical treatment before embryo transfer improves outcomes in women w...

FDA grants Priority Review to Roche's polatuzumab vedotin in previously treated aggressive lymphoma

F. Hoffmann-La Roche Ltd / FDA grants Priority Review to Roche's polatuzumab vedotin in previously treated aggressive lymphoma . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement. Diffuse large B-cell lymphoma is an aggressive type of blood cancer that typically becomes harder to treat each time it returns...

FDA Grants Priority Review to Genentech’s Polatuzumab Vedotin in Previously Treated Aggressive Lymphoma

-- Diffuse large B-cell lymphoma is an aggressive type of blood cancer that typically becomes harder to treat each time it returns -- -- Polatuzumab vedotin has shown significant potential to improve outcomes in people living with this disease -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced tha...

Monday 18th February 2019

[Comment] The global burden of enteric fevers in the age of typhoid-conjugate vaccines

In The Lancet Infectious Diseases, authors led by the Institute of Health Metrics and Evaluation (University of Washington, Seattle, WA, USA) add to our understanding of enteric fevers by presenting a comprehensive and systematic analysis of the global burden of typhoid and paratyphoid fevers using data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017.1 Unlike previo...

Unexpected Genetic Vulnerability to Menthol Cigarette Use

Unexpected Genetic Vulnerability to Menthol Cigarette Use Reporter: Irina Robu, PhD According to a study published in PLOS genetics, a group of international researchers supported by U.S. Food and Drug Administration and the National Institute of Health have found a genetic variant of MRGPRX4 gene in people of African descent that increases a smoker’s preference […]


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks